百奥赛图-B2023 中期报告

百奧賽圖北京醫藥科技股份有限公司 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (A joint stock company incorporated in the People’s Republic of China with limited liability)（於中華人民共和國註冊成立的股份有限公司） Stock code股份代號：2315 Interim Report中 期 報 告2023 Contents 2Corporate Information 6Financial Summary 7Management Discussion and Analysis 51Corporate Governance and Other Information 77Consolidated Statements of Profit or Loss and OtherComprehensive Income 78Consolidated Statements of Financial Position 81Condensed Consolidated Cash Flows Statements 82Notes to the Unaudited Interim Financial Report107Definition Corporate Information CHINESE NAME () ENGLISH NAME BiocytogenPharmaceuticals(Beijing)Co., Ltd.* Biocytogen Pharmaceuticals (Beijing) Co., Ltd.* STOCK CODE02315 02315 LEGAL REPRESENTATIVEDr. Shen Yuelei CHAIRMAN OF THE BOARDDr. Shen Yuelei HEAD OFFICE AND PRINCIPLE PLACEOF BUSINESS IN CHINA 12 12 Baoshen South StreetDaxing Bio-Medicine Industry ParkDaxing District, BeijingPRC REGISTERED OFFICE 12 12 Baoshen South StreetDaxing Bio-Medicine Industry ParkDaxing District, BeijingPRC PRINCIPAL PLACE OF BUSINESS IN HONGKONG 40th Floor, Dah Sing Financial CenterNo. 248 Queen’s Road EastWanchaiHong Kong 24840 * *For identification purpose only Corporate Information BOARD OF DIRECTORS Executive Directors Dr. Shen Yuelei(Chairman, chief executive officer and general manager)Dr. Ni JianDr. Zhang Haichao(Senior operation director of animal center) Non-executive Directors Mr. Wei YiliangDr. Zhou KexiangMs. Zhang Leidi Independent Non-executive Directors Mr. Hua FengmaoDr. Yu ChangyuanMs. Liang Xiaoyan SUPERVISORS Ms. Li YanMs. Sun ChunliDr. Yao Jiawei AUDIT COMMITTEE Ms. Liang Xiaoyan(Chairman)Mr. Hua FengmaoDr. Yu ChangyuanMr. Wei Yiliang REMUNERATION AND EVALUATION COMMITTEE Mr. Hua Fengmao(Chairman)Ms. Liang XiaoyanDr. Yu ChangyuanDr. Ni Jian Corporate Information NOMINATION COMMITTEE Dr. Yu Changyuan(Chairman)Mr. Hua FengmaoMs. Liang XiaoyanDr. Shen Yuelei STRATEGY DEVELOPMENT COMMITTEE Dr. Shen Yuelei(Chairman)Dr. Zhou KexiangMr. Wei YiliangMs. Zhang Leidi JOINT COMPANY SECRETARIES Mr. Wang YongliangMs. Au Wai Ching(associate member of The Hong Kong CharteredGovernance Institute and The Chartered Governance Institutein the United Kingdom) AUTHORIZED REPRESENTATIVES Dr. Shen YueleiMs. Au Wai Ching AUDITOR KPMGCertified Public AccountantsPublic Interest Entity Auditor registered in accordance with theAccounting and Financial Reporting Council Ordinance8th Floor, Prince’s Building10 Chater RoadCentral, Hong Kong 108 Corporate Information COMPLIANCE ADVISOR 18127 Guotai Junan Capital Limited27/F, Low BlockGrand Millennium Plaza181 Queen’s Road CentralHong Kong H H SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong LEGAL ADVISERS TO HONG KONG LAW 3A10 Davis Polk & Wardwell10th Floor, The Hong Kong Club Building3A Chater Road, Hong Kong PRINCIPAL BANKS 2 ChinaConstruction Bank Beijing Economic and TechnologicalDevelopment Zone Sub-branchNo. 2, Jingyuan North StreetDaxing DistrictBeijing, PRC 881 China Merchants Bank, Beijing Yizhuang Sub-branch1/F, Building 8, Libao PlazaNo. 8 Ronghua Middle RoadDaxing DistrictBeijing, PRC COMPANY WEBSITE http://www.biocytogen.com.cn http://www.biocytogen.com.cn CONTACT INFORMATION FOR INVESTORS +86 010-56967601+86 010-56967666-8067ir@bbctg.com.cn Tel.: +86 010-56967601Fax: +86 010-56967666-8067Email: ir@bbctg.com.cn Financial Summary Management Discussion and Analysis I. I.BUSINESS REVIEW Overview 2009IND Foundedin 2009,we are a global biotechnology companydedicatedto novel antibody drug discovery and pre-clinicalresearch services. Unlike traditional chemical drugs, which aresynthesized by drug manufacturers through precise formulations,biopharmaceuticalsare manufactured in living organisms andare more complex protein molecules. The pre-clinical researchservices industry mainly consists of pre-IND drug discovery andpre-clinical pharmacology and efficacy evaluation services. Drugdiscovery is a systematic process that requires interdisciplinarycollaboration to develop effective and commercially viable drugs,and early drug discovery is the foundation for drug transfer. Since the second half of 2022, due to the impact of the globalmacroeconomicsituation,the financing situation and businessoperating environment of the global biopharmaceutical industryhavefaced severe challenges,and the Chinese market hasalsobeen seriously affected,with biopharmaceutical andbiotechnology companies making adjustments by reducing theirdrug pipelines and scaling back R&D expenditures, among otherthings. In the face of the severe external environment, we havealso been making internal adjustments to better cope with thechallenges. Focusing our resources, we have, on the one hand,relied on our technological advantages in various business linesto further develop overseas markets and maintain rap